Development of a UPLC-ESI-MS/MS method for the determination of larotaxel in beagle dog plasma: Application to the pharmacokinetic study

Analytical and Bioanalytical Chemistry

Volumn 403, Issue 1, 2012, Pages 323-330

  Liu, Zhenzhen ^a   Zhang, Bo ^b   Liu, Zhihong ^a   Li, Song ^a   Li, Guofei ^a   Geng, Lulu ^a   Zhao, Xu ^a   Bi, Kaishun ^a   Tang, Xing ^a   Chen, Xiaohui ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b LIAONING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Intravenous administration; Larotaxel loaded lipid microsphere; Pharmacokinetics; UPLC ESI MS MS

Indexed keywords

ACQUITY; AMMONIUM ACETATE; ANALYTES; BEAGLE DOG; CONCENTRATION-TIME; INTERNAL STANDARDS; INTRAVENOUS ADMINISTRATION; LINEAR RANGE; LIQUID-LIQUID EXTRACTION; METHYL TERT BUTYL ETHER; MOBILE PHASE; MULTIPLE-REACTION MONITORING MODES; PEAK CONCENTRATIONS; PHARMACOKINETIC STUDIES; PLASMA SAMPLES; POSITIVE ELECTROSPRAY IONIZATION; RELATIVE ERRORS; RELATIVE STANDARD DEVIATIONS; RUNTIMES; UPLC-ESI-MS/MS; VALIDATED METHODS;

ACETONITRILE; AMMONIUM COMPOUNDS; ELECTROSPRAY IONIZATION; MICROSPHERES; SOLVENT EXTRACTION;

PHARMACOKINETICS;

ANTINEOPLASTIC AGENT; LAROTAXEL; TAXOID;

ANIMAL; ARTICLE; BLOOD; DOG; ELECTROSPRAY MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY; METHODOLOGY; VALIDATION STUDY;

ANIMALS; ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, LIQUID; DOGS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TAXOIDS;

CANIS FAMILIARIS;

EID: 84862794286     PISSN: 16182642     EISSN: 16182650     Source Type: Journal    
DOI: 10.1007/s00216-012-5763-7     Document Type: Article

References (25)

1. MF Otto M Camilo A Evandro A Awada 2009 Larotaxel: broadening the road with new taxanes Expet Opin Investig Drugs 18 1183 1189 10.1517/ 13543780903119167
2. S Drori GD Eytan YG Assaraf 1995 Potentiation of anticancer-drug cytotoxicity by multidrug-resistance chemosensitizers involves alteration in membrane fluidity leading to increased membrane permeability Eur J Biochem 228 1020 1029 10.1111/j.1432-1033.1995.tb20352.x 1:CAS:528:DyaK2MXksl2qtbc%3D
3. DW Nyman KJ Campbell E Hersh K Long K Richardson V Trieu N Desai MJ Hawkins DD Von Hoff 2005 Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies J Clin Oncol 23 7785 7793 10.1200/JCO.2004.00.6148 1:CAS:528:DC%2BD2MXht1Cqs7nI
4. ML Immordino P Brusa S Arpicco B Stella F Dosio L Cattel 2003 Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel J Contr Release 91 417 429 10.1016/S0168-3659(03)00271-2 1:CAS:528:DC%2BD3sXmsVSrtrY%3D
5. A Sparreboom M Zhao JR Brahmer J Verweij SD Baker 2002 Determination of the docetaxel vehicle, polysorbate 80, in patient samples by liquid chromatography-tandem mass spectrometry J Chromatogr B 773 183 190 10.1016/S1570-0232(02)00167-8 1:CAS:528:DC%2BD38Xlt1SiurY%3D
6. PG Morris MN Fornier 2008 Microtubule active agents: beyond the taxane frontier Clin Cancer Res 14 7167 10.1158/1078-0432.CCR-08-0169 1:CAS:528:DC%2BD1cXhtlyltbfO
7. ML Hensley LM Schuchter C Lindley NJ Meropol G Cohen G Broder WJ Gradishar DM Green RJ Langdon Jr RB Mitchell R Negrin TP Szatrowski JT Thigpen D VonHoff T Wasserman E Winer DG Pfister 1999 American Society of Clinical oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants J Clin Oncol 17 3333 3355 1:STN:280: DyaK1MvjvVajtQ%3D%3D
8. KL Hennenfent R Govindan 2006 Novel formulations of taxanes: a review: old wine in a new bottle? Ann Oncol 17 735 749 10.1093/annonc/mdj100 1:STN:280:DC%2BD283jtVKlsw%3D%3D
9. PB Schiff J Fant SB Horwitz 1979 Promotion of microtubule assembly in vitro by taxol Nature 277 665 667 10.1038/277665a0 1:CAS:528:DyaE1MXkvVCitrY%3D
10. JH Fendler A Romero 1977 Liposomes as drug carriers Life Sci 20 1109 1120 10.1016/0024-3205(77)90481-7 1:CAS:528:DyaE2sXksVCit7k%3D
11. JN Weinstein 1984 Liposomes as drug carriers in cancer therapy Canc Treat Rep 68 127 135 1:CAS:528:DyaL2cXls1OjtA%3D%3D
12. NC Philips DPP Thomas CG Night JT Dingle 1979 Liposome incorporated corricosteroids II therapeutic activity in experimental arthritis Ann Rheum Dis 38 553 557 10.1136/ard.38.6.553
13. M Yutaka 1996 Lipid microspheres (lipid emulsions) as a drug carrier-an overview Adv Drug Deliv Rev 20 113 115 10.1016/0169-409X(95)00114-M
14. Y Mizushima T Hammano K Yokoyama 1982 Tissue distribution and anti-inflammatory activity of corticoids incorporated in lipid emulsion Ann Rheum Dis 41 263 267 10.1136/ard.41.3.263 1:CAS:528:DyaL38XlsFKks7s%3D
15. Y Shoji Y Mizushima T Kametani 1986 Affinity of lipid microspheres for MM-46 tumor cells J Pharm Soc Jpn 106 605 608 1:CAS:528:DyaL28Xlt1Slt7s%3D
16. M Takenaga R Igarashi H Tsuji Y Mizushima 1993 Enhanced antitumor activity and reduced toxicity of 1,3-bis-2-chloroethyl-1-nitrosourea administered in lipid microspheres to tumor-bearing mice J Canc Res 84 1078 1085 1:CAS:528:DyaK2cXit1Kltbw%3D
17. T Mitsuko 1996 Application of lipid microspheres for the treatment of cancer Adv Drug Deliv Rev 20 209 219 10.1016/0169-409X(95)00124-P
18. C Sessa C Cuvier S Caldiera J Bauer BS Vanden C Monnerat D Semiond D Perard A Lebecq M Besenval M Marty 2002 Phase I clinical and pharmacokinetic studies of the taxiod derivative RPR 109881A administered as a 1-hour or a 3-hour infusion in patients with advanced solid tumors Ann Oncol 13 1140 1150 10.1093/annonc/mdf174 1:STN:280:DC%2BD38vitFWmsw%3D%3D
19. T Kurata Y Shimada T Tamura N Yamamoto I Hyodo T Saeki S Takashima K Fujiwara H Wakasugi M Kashimura 2000 Phase I and pharmacokinetic study of a new Taxoid, RPR109881A, given as a 1-hour intravenous infusion in patients with advanced solid tumors J Clin Oncol 18 3164 3171 1:CAS:528:DC%2BD3cXntVCgsbk%3D
20. N Yamamoto N Boku H Minami 2009 Phase I study of larotaxel administered as a 1-h intravenous infusion every 3 weeks to Japanese patients with advanced solid tumours Canc Chemother Pharmacol 65 129 136 10.1007/s00280-009-1014-9 1:CAS:528:DC%2BD1MXhtFegu7%2FP
21. A De Villiers F Lestremau R Szucs F David P Sandra 2006 Evaluation of ultra performance liquid chromatography J Chromatogr A 1127 60 69 10.1016/j.chroma.2006.05.071
22. MI Churchwell NC Twaddle LR Meeker DR Doerge 2005 Improving LC-MS sensitivity through increases in chromatographic performance: comparisons of UPLC-ES/MS/MS to HPLC-ES/MS/MS J Chromatogr B 825 134 143 10.1016/j.jchromb. 2005.05.037 1:CAS:528:DC%2BD2MXhtVyms7fN
23. S Pedraglio MG Rozio P Misiano V Reali G Dondio C Bigogno 2007 New perspectives in bio-analytical techniques for preclinical characterization of a drug candidate: UPLC-MS/MS in vitro metabolism and pharmacokinetic studies J Pharm Biomed Anal 44 665 673 10.1016/j.jpba.2006.12.012 1:CAS:528: DC%2BD2sXnslWhsbk%3D
24. ICH (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use) (2009) Preclinical safety evaluation of biotechnology-derived pharmaceuticals S6 (R1). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM194490.pdf
25. CDER (Center for Drug Evaluation and Research) (2001) Guidance for industry, bioanalytical method validation, US FDA. http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf